What's in SURPRISE Study Group's pipeline?

SURPRISE Study Group has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with SURPRISE Study Group's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/surprise-study-group.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

SURPRISE Study Group — Portfolio Competitive Intelligence Brief

SURPRISE Study Group pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Tocilizumab plus methotrexate	Tocilizumab plus methotrexate	marketed	IL-6 receptor antagonist + DMARD combination	IL-6 receptor (tocilizumab); dihydrofolate reductase (methotrexate)	Immunology

Therapeutic area mix

Immunology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for SURPRISE Study Group:

Cite this brief

Drug Landscape (2026). SURPRISE Study Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/surprise-study-group. Accessed 2026-05-14.